Skip to main content
MedPathMedPath Home
Clinical Trials/ISRCTN41688895
ISRCTN41688895
Active, not recruiting
未知

Progression in Multiple Sclerosis

Cambridge University Hospitals NHS Foundation Trust0 sites10,000 target enrollmentMay 4, 2023
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsMultiple sclerosisNervous System Diseases

Overview

Phase
未知
Intervention
Not specified
Conditions
Multiple sclerosis
Sponsor
Cambridge University Hospitals NHS Foundation Trust
Enrollment
10000
Status
Active, not recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 4, 2023
End Date
June 1, 2025
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •1\. A locally confirmed diagnosis of multiple sclerosis
  • •2\. At least one measure of Extended Disability Severity Score (EDSS)
  • •3\. Able to give valid informed consent

Exclusion Criteria

  • •1\. Patients with Radiologically or Clinically Isolated Syndrome (RIS or CIS)
  • •2\. Comorbidities causing significant disability likely to have confounded the reliability of the EDSS
  • •3\. Inclusion in the discovery cohort of the recently completed first progression GWAS

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Phase 3
Treatment of Progressive Multiple Sclerosis-related Cognitive Impairment, Fatigue, and Depression Using Repetitive Transcranial Magnetic StimulatioNervous System Diseases
PACTR202403516079512Science Technology and Innovation Funding Authority60
Active, not recruiting
Phase 1
Phase IIIB-IV long term follow-up study for patients who participated in CAMMS03409Relapsing-remitting multiple sclerosisMedDRA version: 21.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]
EUCTR2013-003884-71-CZGenzyme Corporation1,248
Active, not recruiting
Phase 1
Phase IIIB-IV long term follow-up study for patients who participated in CAMMS03409
EUCTR2013-003884-71-ITGenzyme Corporation799
Active, not recruiting
Phase 1
Phase IIIB-IV long term follow-up study for patients who participated in CAMMS03409Relapsing-remitting multiple sclerosisMedDRA version: 21.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]
EUCTR2013-003884-71-NLGenzyme Corporation1,248
Active, not recruiting
Phase 1
Phase IIIB-IV long term follow-up study for patients who participated in CAMMS03409
EUCTR2013-003884-71-DKGenzyme Corporation1,248